Healthwell Acquisition Corp. I - HWELU STOCK NEWS

Welcome to our dedicated page for Healthwell Acquisition I news (Ticker: HWELU), a resource for investors and traders seeking the latest updates and insights on Healthwell Acquisition I stock.

Healthwell Acquisition Corp. I (HWELU) is a special purpose acquisition company (SPAC) focused on acquiring a company in the healthcare industry. They aim to identify a target business with promising growth prospects and a strong management team to merge with. Healthwell Acquisition Corp. I is led by experienced executives with a track record of successful acquisitions and value creation.

11/17/2023 09:29 PM

News

Healthwell Acquisition Corp. I Announces Cancellation of Special Stockholder Meeting and its Intention to Liquidate

Rhea-AI Summary

Healthwell Acquisition Corp. I (Nasdaq: HWEL) has canceled its special meeting of stockholders, withdrawn proposals, and decided to liquidate, redeeming shares of its Class A common stock at an estimated price of $10.50 per share. The company's sponsor has waived its redemption rights, and there will be no redemption rights or liquidating distributions for warrants.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.25%

Tags

11/03/2023 07:00 PM

News

Healthwell Acquisition Corp. I Announces Termination of Business Combination with Starton Therapeutics, Inc.

Rhea-AI Summary

Healthwell Acquisition Corp. I (Nasdaq: HWEL) announced the termination of its Business Combination Agreement with Starton Therapeutics, Inc. The closing conditions were not met by the outside date of November 3, 2023, and Healthwell will now pursue an alternative business combination.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.78%

Tags

11/03/2023 06:00 PM

News

Starton Therapeutics Announces Termination of Business Combination Agreement with Healthwell Acquisition Corp. I

Rhea-AI Summary

Starton Therapeutics Inc. has terminated its business combination agreement with Healthwell Acquisition Corp. The conditions for closing the agreement were not met or waived by the deadline. The termination will not affect certain specified provisions in the agreement. Starton has initiated its Phase 1b STAR-LLD clinical trial in multiple myeloma and remains committed to completing the study.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.78%

Tags

10/17/2023 06:00 AM

News

Healthwell Acquisition Corp. I Announces New Meeting Date for the Special Meeting of Stockholders to Approve Proposed Business Combination With Starton Therapeutics, Inc. and Related Transactions

Rhea-AI Summary

Healthwell Acquisition Corp. I (NASDAQ: HWEL) has postponed its special meeting of stockholders to approve its proposed business combination with Starton Therapeutics, Inc. The new meeting date is October 25, 2023. Stockholders are encouraged to vote before October 24, 2023. Redemption rights are also available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.68%

Tags

10/04/2023 08:00 AM

News

Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

Rhea-AI Summary

Starton Therapeutics announces dosing of first patient in Phase 1b clinical trial for low-dose lenalidomide in multiple myeloma treatment.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

09/13/2023 04:05 PM

News

Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phase 1b Trial in Multiple Myeloma

Rhea-AI Summary

Gabrail Cancer & Research Center activated as the first site in Starton's clinical trial, accelerating their program timeline. Dr. Gabrail believes in the importance of clinical trials for cancer patients. GCC has a national reputation for excellence in patient care and attracts patients nationally and internationally. Dosing expected to begin in the coming weeks.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

07/10/2023 07:00 AM

News

Starton Therapeutics Contracts Global Clinical Research Organization to Conduct STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/12/2023 04:30 PM

News

Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

Rhea-AI Summary

Starton Therapeutics has received FDA approval to proceed with its Phase 1b study of continuous delivery lenalidomide in multiple myeloma. The study will evaluate the combination of STAR-LLD, Velcade, and dexamethasone in second-line transplant-ineligible patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/06/2023 08:00 AM

News

Starton Therapeutics, Inc. and Healthwell Acquisition Corp. I to Present at the Jefferies Healthcare Conference

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.88%

Tags

04/27/2023 07:00 AM

News

Starton Therapeutics Inc. and Healthwell Acquisition Corp. I to Combine and Create Publicly Traded Leader in Proprietary Continuous Delivery Technology for Cancer Treatments

Rhea-AI Summary

Starton Therapeutics has announced a definitive business combination agreement with Healthwell Acquisition Corp. I (HWEL) to facilitate Starton’s transition to a publicly traded entity. Post-transaction, the combined entity is projected to have an enterprise value of $339 million and equity value of $374 million. Starton anticipates $50 million in net proceeds from the transaction to fund future clinical trials, including its lead program STAR-LLD targeting hematologic cancers. The transaction is expected to close in the second half of 2023, subject to shareholder approval. With innovative proprietary continuous delivery technology, Starton aims to enhance treatment efficacy and tolerability for cancer patients, potentially transforming blood cancer therapies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is Healthwell Acquisition Corp. I?

Healthwell Acquisition Corp. I (HWELU) is a special purpose acquisition company (SPAC) focused on acquiring a company in the healthcare industry.

What is the focus of Healthwell Acquisition Corp. I?

Healthwell Acquisition Corp. I focuses on identifying a target business with promising growth prospects and a strong management team to merge with.

Who leads Healthwell Acquisition Corp. I?

Healthwell Acquisition Corp. I is led by experienced executives with a track record of successful acquisitions and value creation.

What is the goal of Healthwell Acquisition Corp. I?

The goal of Healthwell Acquisition Corp. I is to merge with a company in the healthcare industry that offers potential for growth and value creation.

What sets Healthwell Acquisition Corp. I apart?

Healthwell Acquisition Corp. I stands out for its focus on the healthcare sector and its leadership team's expertise in acquisitions and value creation.

How does Healthwell Acquisition Corp. I operate?

Healthwell Acquisition Corp. I operates as a SPAC, seeking to identify and merge with a target company in the healthcare industry.

What are the benefits of investing in Healthwell Acquisition Corp. I?

Investing in Healthwell Acquisition Corp. I offers the potential for returns through its acquisition and merger activities in the healthcare sector.

What is the strategy of Healthwell Acquisition Corp. I?

The strategy of Healthwell Acquisition Corp. I is to leverage its industry expertise and network to identify and merge with a promising company in the healthcare sector.

What can investors expect from Healthwell Acquisition Corp. I?

Investors can expect Healthwell Acquisition Corp. I to provide updates on its acquisition progress, potential mergers, and growth opportunities in the healthcare industry.

How can I stay informed about Healthwell Acquisition Corp. I?

Stay updated on the latest news and developments of Healthwell Acquisition Corp. I by following their announcements and press releases in the healthcare industry.